A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi
Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy
In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir
The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl